Folfox AI by Caris – pro
MI FOLFOXai™is an Artificial Intelligence (AI)-based predictor of response to FOLFOX chemotherapy in metastatic colorectal cancer that demonstrated approximately 50 percent improvement in overall survival across two independent validation studies. Using Caris Molecular Intelligence® tumor profiling results, this AI-powered predictor is intended to gauge a patient’s likelihood of benefit from FOLFOX as a first-line regimen in combination with bevacizumab.
MI FOLFOXai was validated using two independent data sets to compare the increased benefit arm to the decreased benefit arm. The first study was a blinded, prospective analysis from retrospectively tested samples from the randomized Phase III TRIBE2 study. This study showed a median overall survival improvement of 6.9 months. The second study involved several hundred cases with real-world evidence that showed a median overall survival increase of 11.8 months.
MI FOLFOXai was developed using a subset of results from the company’s proprietary Caris Molecular Intelligence platform, which includes next generation sequencing for DNA mutations, copy number alterations, insertions/deletions; whole transcriptome sequencing for RNA fusions and variant transcripts; and protein testing via immunochemistry. Machine learning algorithms were then used to create a molecular signature that was validated using the two independent data sets to compare the increased benefit arm to the decreased benefit arm.
This test remains proprietary and not validated by outside sources.
NCCN, Colorectal Cancer 2020
Abraham JP, Magee D, Cremolini C, et al. Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer. Clin Cancer Res. Published online December 3, 2020. doi:10.1158/1078-0432.CCR-20-3286